FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120333793> ?p ?o ?g. }

• W2120333793 endingPage "2827" @default.
• W2120333793 startingPage "2820" @default.
• W2120333793 abstract "Neoadjuvant therapy has been investigated for localized and locally advanced pancreatic ductal adenocarcinoma (PDAC) but no standard of care exists. Combination cetuximab/gemcitabine/radiotherapy demonstrates encouraging preclinical activity in PDAC. We investigated cetuximab with twice-weekly gemcitabine and intensity-modulated radiotherapy (IMRT) as neoadjuvant therapy in patients with localized or locally advanced PDAC.Treatment consisted of cetuximab load at 400 mg/m(2) followed by cetuximab 250 mg/m(2) weekly and gemcitabine 50 mg/m(2) twice-weekly given concurrently with IMRT to 54 Gy. Following therapy, patients were considered for resection.Thirty-seven patients were enrolled with 33 assessable for response. Ten patients (30%) manifested partial response and 20 (61%) manifested stable disease by RECIST. Twenty-five patients (76%) underwent resection, including 18/23 previously borderline and 3/6 previously unresectable tumors. Twenty-three (92%) of these had negative surgical margins. Pathology revealed that 24% of resected tumors had grade III/IV tumor kill, including two pathological complete responses (8%). Median survival was 24.3 months in resected patients. Outcome did not vary by epidermal growth factor receptor status.Neoadjuvant therapy with cetuximab/gemcitabine/IMRT is tolerable and active in PDAC. Margin-negative resection rates are high and some locally advanced tumors can be downstaged to allow for complete resection with encouraging survival. Pathological complete responses can occur. This combination warrants further investigation." @default.
• W2120333793 created "2016-06-24" @default.
• W2120333793 creator A5001118529 @default.
• W2120333793 creator A5001250550 @default.
• W2120333793 creator A5003642570 @default.
• W2120333793 creator A5012277710 @default.
• W2120333793 creator A5021354001 @default.
• W2120333793 creator A5028691600 @default.
• W2120333793 creator A5031786134 @default.
• W2120333793 creator A5033145928 @default.
• W2120333793 creator A5040192785 @default.
• W2120333793 creator A5041213698 @default.
• W2120333793 creator A5043541212 @default.
• W2120333793 creator A5043723133 @default.
• W2120333793 creator A5044499035 @default.
• W2120333793 creator A5045555694 @default.
• W2120333793 creator A5052428479 @default.
• W2120333793 creator A5080507506 @default.
• W2120333793 creator A5081988343 @default.
• W2120333793 creator A5086314355 @default.
• W2120333793 creator A5087377374 @default.
• W2120333793 date "2012-11-01" @default.
• W2120333793 modified "2023-10-17" @default.
• W2120333793 title "Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma" @default.
• W2120333793 cites W118213103 @default.
• W2120333793 cites W141769504 @default.
• W2120333793 cites W1527076593 @default.
• W2120333793 cites W1982297289 @default.
• W2120333793 cites W1994177577 @default.
• W2120333793 cites W1998777645 @default.
• W2120333793 cites W2008803651 @default.
• W2120333793 cites W2010249718 @default.
• W2120333793 cites W2012987137 @default.
• W2120333793 cites W2024477013 @default.
• W2120333793 cites W2025313715 @default.
• W2120333793 cites W2034880967 @default.
• W2120333793 cites W2043046437 @default.
• W2120333793 cites W2074121131 @default.
• W2120333793 cites W2077003423 @default.
• W2120333793 cites W2090448540 @default.
• W2120333793 cites W2103607678 @default.
• W2120333793 cites W2122849674 @default.
• W2120333793 cites W2132945301 @default.
• W2120333793 cites W2136935697 @default.
• W2120333793 cites W2139248078 @default.
• W2120333793 cites W2140024351 @default.
• W2120333793 cites W2142809913 @default.
• W2120333793 cites W2144717403 @default.
• W2120333793 cites W2151253787 @default.
• W2120333793 cites W2159506251 @default.
• W2120333793 cites W2163958696 @default.
• W2120333793 cites W2165912385 @default.
• W2120333793 cites W2319130292 @default.
• W2120333793 cites W2439217830 @default.
• W2120333793 doi "https://doi.org/10.1093/annonc/mds109" @default.
• W2120333793 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3577039" @default.
• W2120333793 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22571859" @default.
• W2120333793 hasPublicationYear "2012" @default.
• W2120333793 type Work @default.
• W2120333793 sameAs 2120333793 @default.
• W2120333793 citedByCount "38" @default.
• W2120333793 countsByYear W21203337932013 @default.
• W2120333793 countsByYear W21203337932014 @default.
• W2120333793 countsByYear W21203337932015 @default.
• W2120333793 countsByYear W21203337932016 @default.
• W2120333793 countsByYear W21203337932017 @default.
• W2120333793 countsByYear W21203337932019 @default.
• W2120333793 countsByYear W21203337932020 @default.
• W2120333793 countsByYear W21203337932021 @default.
• W2120333793 countsByYear W21203337932022 @default.
• W2120333793 crossrefType "journal-article" @default.
• W2120333793 hasAuthorship W2120333793A5001118529 @default.
• W2120333793 hasAuthorship W2120333793A5001250550 @default.
• W2120333793 hasAuthorship W2120333793A5003642570 @default.
• W2120333793 hasAuthorship W2120333793A5012277710 @default.
• W2120333793 hasAuthorship W2120333793A5021354001 @default.
• W2120333793 hasAuthorship W2120333793A5028691600 @default.
• W2120333793 hasAuthorship W2120333793A5031786134 @default.
• W2120333793 hasAuthorship W2120333793A5033145928 @default.
• W2120333793 hasAuthorship W2120333793A5040192785 @default.
• W2120333793 hasAuthorship W2120333793A5041213698 @default.
• W2120333793 hasAuthorship W2120333793A5043541212 @default.
• W2120333793 hasAuthorship W2120333793A5043723133 @default.
• W2120333793 hasAuthorship W2120333793A5044499035 @default.
• W2120333793 hasAuthorship W2120333793A5045555694 @default.
• W2120333793 hasAuthorship W2120333793A5052428479 @default.
• W2120333793 hasAuthorship W2120333793A5080507506 @default.
• W2120333793 hasAuthorship W2120333793A5081988343 @default.
• W2120333793 hasAuthorship W2120333793A5086314355 @default.
• W2120333793 hasAuthorship W2120333793A5087377374 @default.
• W2120333793 hasBestOaLocation W21203337931 @default.
• W2120333793 hasConcept C121608353 @default.
• W2120333793 hasConcept C126322002 @default.
• W2120333793 hasConcept C126838900 @default.
• W2120333793 hasConcept C143998085 @default.
• W2120333793 hasConcept C2776694085 @default.
• W2120333793 hasConcept C2778292576 @default.
• W2120333793 hasConcept C2779984678 @default.

• next